Do Covid-19 patients needing ICU admission have worse 6 months follow up outcomes when compared with hospitalized non-ICU patients? A prospective cohort study

suleyman yildirim[1], Seher Susam[2], Pınar Cimen[2], Sena Yapicioglu[2], Onur Sunecli[2], Özlem Ediboglu[2], and Cenk Kirakli[2]

[1]Doktor Suat Seren Gogus Hastaliklari ve Cerrahisi Egitim ve Arastirma Hastanesi
[2]University of Health Sciences Turkey, Dr Suat Seren Chest Diseases and Chest Surgery Training and Research Hospital

March 07, 2024

Abstract

Objectives Long-term outcomes of COVID-19 patients who discharge ICU are unclear. We investigated the effect of COVID-19 on lung structure, pulmonary functional, exercise capacity and quality of life in patients discharge from ICU and medical ward. Methods A prospective single-centre study conducted in PCR confirmed COVID-19 patients who has been discharged from University of Health Sciences, Dr. Suat Seren Chest Disease and Thoracic Surgery Teaching and Research Hospital between 15 January and 5 March 2021. Patients who followed up for more than 48 hours in ICU and more than 72 hours in medical ward were included the study. Computed tomography scores, pulmonary functional tests (PFT), 6-min walking distance and health related quality of life by SF-36 were compared between ICU and medical ward patients at 6 months after discharge. Results Seventy patients were included final analyses and 31 of them discharged from ICU. ICU patients had higher CT scores than non-ICU patients at admission (17 vs 11) and follow up visit (6 vs 0). Two-three of ICU patients had at least one abnormal finding at control CT. Advanced age (OR 1.08, 95% CI 1.02-1.15) and higher CT score at admission (OR 1.13, 95% CI 1.01-1.27) were risk factors for having radiological abnormalities at control CT. 90% of the patients discharged from the ICU had at least one persistent symptom. Conclusion A number of COVID-19 survivors could not fully recover after 6 months of hospital discharge. COVID-19 survivor needs to support therapies at recovery phase of the disease.

Do Covid-19 patients needing ICU admission have worse 6 months follow up outcomes when compared with hospitalized non-ICU patients? A prospective cohort study

Süleyman Yıldırım[1], Seher Susam[2], Pınar Cimen[3], Sena Yapicioglu[3], Onur Sunecli[4], Özlem Ediboglu[1], Cenk Kirakli[1]

[1]University of Health Sciences Turkey, Dr. Suat Seren Chest Disease and Chest Surgery Training and Research Hospital, Intensive Care Unit, İzmir, Turkey

[2]University of Health Sciences Turkey, Dr. Suat Seren Chest Disease and Chest Surgery Training and Research Hospital, Department of Radiology, İzmir, Turkey

[3]University of Health Sciences Turkey, Dr. Suat Seren Chest Disease and Chest Surgery Training and Research Hospital Turkey, Department of Chest Disease, İzmir, Turkey

[4]University of Health Sciences Turkey, Dr. Suat Seren Chest Disease and Chest Surgery Training and Research Hospital, Department of Physiotherapy, İzmir, Turkey

Corresponding Address

Cenk Kirakli M.D.

[1]University of Health Sciences Turkey, Dr. Suat Seren Chest Disease and Chest Surgery Training and Research Hospital, Intensive Care Unit, İzmir, Turkey

Telephone Number: +902324333333

e-mail:*samicenk.kirakli@sbu.edu.tr*

Orcid ID: 0000-0001-6013-7330

Authors' declaration: The authors declare that the submitted work is their own and that copyright has not been breached in seeking its publication. They confirm that the article is an original work, has not been published before, and is not being considered for publication elsewhere in its final form, in either printed or electronic media.

Conflict of Interest: The authors declare that they have no conflict of interest.

Ethics approval and consent to participate: The study was approved by the ethics committee of University of Health Sciences, Dr. Suat Seren Chest Disease and Thoracic Surgery Teaching and Research Hospital (ethical approval number: 19-28.09.2020). Written informed consent was obtained from all participants.

Word count of abstract: 247 words (<250 words)

Word count of text: 2411 words (<3000 words)

Number of tables: 4

Short title: Long-term outcomes of COVID-19

Authors' Contributions: SY, SS, ÖE and CK designed the study. SY, SS, PC, SY and OS recorded the data. SY, ÖE and CK analysed the data. All authors contributed the interpretation of data. SY and CK drafted the first version of the manuscript. All authors contributed drafting the manuscript and all authors approved the final version of manuscript.

Süleyman Yıldırım M.D.

[1]University of Health Sciences Turkey, Dr. Suat Seren Chest Disease and Chest Surgery Training and Research Hospital, Intensive Care Unit, İzmir, Turkey

Telephone Number: 902324333333

e-mail address:*deu.syldrm@gmail.com*

Orcid ID: 0000-0001-9856-3431

Seher Susam M.D.

[2]University of Health Sciences Turkey, Dr. Suat Seren Chest Disease and Chest Surgery Training and Research Hospital, Department of Radiology, İzmir, Turkey

Telephone Number: 902324333333

e-mail address:*sehersusam@gmail.com*

Pınar Cimen M.D.

[3]University of Health Sciences Turkey, Dr. Suat Seren Chest Disease and Chest Surgery Training and Research Hospital, Department of Chest Disease, İzmir, Turkey

Telephone Number: 902324333333

e-mail address:*drpcimen@hotmail.com*

Sena Yapicioglu M.D.

[3]University of Health Sciences Turkey, Dr. Suat Seren Chest Disease and Chest Surgery Training and Research Hospital, Department of Chest Disease, İzmir, Turkey

Telephone Number: 902324333333

e-mail address:*senayapicioglu@hotmail.com*

Onur Sunecli

[4]University of Health Sciences Turkey, Dr. Suat Seren Chest Disease and Chest Surgery Training and Research Hospital, Department of Physiotherapy, İzmir, Turkey

Telephone Number: 902324333333

e-mail address:*suneclionur@gmail.com*

Özlem Ediboglu M.D.

[1]University of Health Sciences Turkey, Dr. Suat Seren Chest Disease and Chest Surgery Training and Research Hospital, Intensive Care Unit, İzmir, Turkey

Telephone Number: 902324333333

e-mail address:*ozlemediboglu@gmail.com*

Cenk Kirakli M.D.

[1]University of Health Sciences Turkey, Dr. Suat Seren Chest Disease and Chest Surgery Training and Research Hospital, Intensive Care Unit, İzmir, Turkey

Telephone Number: +902324333333

e-mail:*samicenk.kirakli@sbu.edu.tr*

Orcid ID: 0000-0001-6013-7330

Abstract

Objectives

Long-term outcomes of COVID-19 patients who discharge ICU are unclear. We investigated the effect of COVID-19 on lung structure, pulmonary functional, exercise capacity and quality of life in patients discharge from ICU and medical ward.

Methods

A prospective single-centre study conducted in PCR confirmed COVID-19 patients who has been discharged from University of Health Sciences, Dr. Suat Seren Chest Disease and Thoracic Surgery Teaching and Research Hospital between 15 January and 5 March 2021. Patients who followed up for more than 48 hours in ICU and more than 72 hours in medical ward were included the study. Computed tomography scores, pulmonary functional tests (PFT), 6-min walking distance and health related quality of life by SF-36 were compared between ICU and medical ward patients at 6 months after discharge.

Results

Seventy patients were included final analyses and 31 of them discharged from ICU. ICU patients had higher CT scores than non-ICU patients at admission (17 vs 11) and follow up visit (6 vs 0). Two-three of ICU patients had at least one abnormal finding at control CT. Advanced age (OR 1.08, 95% CI 1.02-1.15)

and higher CT score at admission (OR 1.13, 95% CI 1.01-1.27) were risk factors for having radiological abnormalities at control CT. 90% of the patients discharged from the ICU had at least one persistent symptom.

Conclusion

A number of COVID-19 survivors could not fully recover after 6 months of hospital discharge. COVID-19 survivor needs to support therapies at recovery phase of the disease.

This study was registered on clinicaltrials.gov under the number NCT04715919

Keywords

COVID-19, ICU patients, CT score, Pulmonary functional test, 6-min walking test

What is already known about this topic?

Previous studies shown that abnormal CT findings and impaired pulmonary functions test were exist in early convalescent phase of COVID-19. Long-term outcomes of COVID-19 patients especially who discharge ICU are unclear.

What does this article add?

In our prospective cohort study, we examine the long-term effects of COVID-19 on lung structures, pulmonary functions, exercise capacity and quality of life in discharged patients. CT findings and symptoms (especially effort dyspnea, fatigue and muscle weakness) may not be totally resolved 6 months after the onset of symptoms in patients who require ICU admission.

Introduction

Coronavirus disease-19 (COVID-19), caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), has affected over 150 million people around the world as of April 28, 2021[1].

The onset symptoms of COVID-19 are fever, fatigue, shortness of breath, and a dry cough[2,3]. Typically chest tomography findings are peripheral, subpleural ground-glass opacities, bilaterally patchy shadows[2,4,5] and chest computed tomography (CT) findings are related to disease severity[6,7]. Although most cases were classified as mild, 14% of cases were severe and 5% of them were critical, requiring intensive care unit (ICU) admission[8]. Studies focus on pathogenesis, clinical manifestations, and complications during the early phase of the disease[9–13], but long-term outcomes still remain unclear.

Some of the patients recovered completely, but some patients were unable to reach their former health status, despite a long recovery period. Symptoms such as fatigue and dyspnea persist in half of the patients who were discharged from hospital[14,15]. CT findings are reversible in the majority of COVID-19 patients[16]. However, data on improvement of CT findings in ICU patients who have higher CT scores are lacking. Complete recovery may take a long time in mild and moderate cases as well as in severe patients who require ICU admission. More studies are needed on long-term outcomes in the post-COVID period[17], especially in ICU patients.

The aim of this study was to evaluate the long-term effects of COVID-19 on lung structures, pulmonary functions, exercise capacity and quality of life in discharged ICU patients and compare these findings with hospitalized non-ICU patients.

Methods

This is a single-centre, prospective cohort study performed between 15 January and 5 March 2021 at the University of Health Sciences, Dr. Suat Seren Chest Disease and Thoracic Surgery Teaching and Research Hospital. This is a tertiary hospital specializing in pulmonary diseases and has been designated for patients with COVID-19 since March 2020. Our study was approved by the ethics committee of University of Health

Sciences, Dr. Suat Seren Chest Disease and Thoracic Surgery Teaching and Research Hospital (ethical approval number: 19-28.09.2020). Written informed consent was obtained from all participants. This study was registered on clinicaltrials.gov under the number NCT04715919.

Patients

Patients who were followed up on for more than 48 hours in ICU and more than 72 hours in medical wards due to COVID-19 between March 19 and September 1, 2020 were included in the study. We excluded the following patients, (1) those who have neurodegenerative diseases, (2) those who were readmitted to the hospital due to any other conditions, (3) those with impaired movement due to physical disabilities. Patients were included in the study for at least 6 months, after discharge from the hospital.

The diagnosis of COVID-19 was based on World Health Organization (WHO) interim guidance[18]. Antiviral treatment against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was given according to Turkish Ministry of Health COVID-19 Guidance[19].

Procedures

Clinical data including demographic characteristics (age, gender, smoking status), antiviral treatment (hydroxychloroquine, favipiravir, convalescent plasma, steroids), chest tomography results and complication development during hospitalization were obtained from the hospital electronic record system. Patients were classified into 2 groups: ICU patients (followed in the ICU due to COVID-19) and non-ICU patients (hospitalized due to COVID-19 but followed in the pulmonary ward).

Patients were invited to the follow-up visit, by healthcare professionals, by telephone. All participants were consulted face to face by an investigator; asked to complete a questionnaire to assess their health status (Short Form-36, SF-36); and asked for persistent symptoms such as dyspnea, fatigue, muscle weakness etc. A trained physiotherapist performed a 6-min walking test to assess functional exercise capacity. The pulmonary function test was performed in the Pulmonary Functional Centre in University of Health Sciences, Dr. Suat Seren Chest Disease and Thoracic Surgery Teaching and Research Hospital according to American Thoracic Society and European Respiratory Society spirometry standardizations[20].

Chest high-resolution computed tomography (HRCT) was performed at the end-inspiration in supine position, 1.25 mm section thickness and 0.625 mm reconstruction with high resolution. An experienced radiologist cross-compared HRCT images during hospital stay and follow-up HRCT images. If a participant had more than one HRCT, final chest images were included in the comparison. Both lungs were divided into 5 lobes in accordance with normal anatomical structure. Each lung lobe was given a score according to the following criteria; 0, no involvement; 1, less than 5% involvement; 2, 5-25% involvement; 3, 25-50% involvement; 4, 50-75% involvement; 5, more than 75% involvement. The total CT score was calculated semi-quantitatively with the sum of the scores of the five lobes[21].

The SF-36 test is a 36-item self-reported survey of quality of life. SF-36 contains eight categories that assess physical functioning, social functioning, role limitation due to physical and emotional problems, general and mental health, bodily pain and vitality. Each category is scored from 0 (worst) to 100 (best) with higher scores showing better quality of life[22]. The translated and validated version of SF-36 was used for the study[23].

The primary outcome was the percentage of patients with lung involvement in the 6-month follow up CT scan.

Secondary outcomes were exercise capacity (distance of 6-min walking test), pulmonary function tests and health state scores at the follow up visit.

Statistical Analyses

Data are expressed as median (IQR) or number (%) where appropriate. Continuous data are compared with the Mann Whitney U test, and categorical data with the Chi square test. According to a study performed

in severe acute respiratory syndrome (SARS), 30% of patients showed abnormal radiological findings at the 6 month follow up[24]. We also hypothesized that Covid 19 patients requiring ICU admission would have a 2-fold increase in the lung involvement at the 6 months follow up CT scan when compared with non-ICU patients. Assuming that 30% of non-ICU patients and 60% of ICU patients will have lung involvement in the 6-month follow-up CT, with a 5% type 1 error and 80% power, 40 patients in each group were needed for the analysis. A p value of <0.05 was considered as significant.

Results

A total of 269 COVID-19 patients were discharged from our hospital between 1 April and 1 September 2020 and 70 patients were included in the study (Figure 1). The demographic and clinical characteristics of the participants are shown in table 1. Median age of participants was 56 years, and 60 (75%) of them were male. Most common comorbid diseases were hypertension (40%) and DM (33%). Thirty-one patients (44%) were admitted to the ICU and the median length of ICU stay was 9 days. Median length of hospital stay was 12 days and the time from the onset of symptoms to follow-up visit was 198 days.

ICU patients had a higher median CT score at admission than non-ICU patients [17 (11-24) vs. 11 (10-15) respectively, p=0.002]. CT scores at the follow-up visit remained higher in ICU patients. All of the patients had at least one CT finding at admission, 20 ICU patients (65%) and 12 non-ICU patients (31%) had at least one CT finding in the follow-up CT (p=0.005) (Table 2). The most common CT finding was ground glass opacity (GGO) in the follow-up CT, followed by subpleural lines and irregular lines.

79% of participants had at least one persistent symptom. Individuals who were discharged from the ICU had a higher percentage of persistent symptoms, 90% vs 67% (p=0.033). Effort dyspnea was the most common persistent symptom followed by fatigue and muscle weakness (e–Table 1). Women had a higher percentage of persistent symptoms than men (e–Table 2).

A total of 65 participants (93%) completed the pulmonary function test (PFT) and 5 participants were unable to complete the test. Results of PFT are summarized at table 3. Forced vital capacity (FVC), peak expiratory flow (PEF) and peak inspiratory flow (PIF) were the most commonly affected parameters in ICU patients. PEF and PIF were also the two most commonly affected parameters in non-ICU patients. Higher CT scores at follow-up visits were found to be associated with impairment of PFT (Table 4).

The median distance of 6-minute walk tests was similar in both groups; 445m in ICU patients, and 461 meters in non-ICU patients. When participants were stratified into age and weight, 13 participants (42%) in the ICU group, and 11 participants (28%) in the non-ICU group, were below 80% of the expected distance.

Assessment of quality of life, by SF-36, were similar in the two groups. Social functioning, role limitation due to physical and emotional problems were the most affected SF-36 categories (Table 3). The quality of life scores were lower in female participants than male participants (e–Table 3).

When the presence of ICU admission, age, gender, and CT score at admission were introduced into a logistic regression model, only patients age (OR 1.08, 95% CI 1.02-1.15) and higher CT score at admission (OR 1.13, 95% CI 1.01-1.27) were independent risk factors for having at least one radiological abnormality at a follow-up CT.

Discussions

The main finding of this study was that the CT findings and symptoms (especially effort dyspnea, fatigue and muscle weakness) may not be totally resolved 6 months after the onset of symptoms in patients who require ICU admission. Also, some of these patients may encounter impaired pulmonary function tests and decreased exercise capacity. Impairment of quality of life was comparable between ICU and non-ICU patients.

Chest CT has been frequently used as a diagnostic tool during the COVID-19 outbreak and CT severity scores were related to disease severity[25]. In our study patients who were admitted to ICU had higher CT scores than patients admitted to the medical ward and this result was consistent with previous studies[25,26].

At the follow-up visit patients who were discharged from ICU had higher CT scores than patients who were discharged from the medical ward (6 vs 0). CT findings were totally resolved in most non-ICU patients, but most ICU patients had abnormal CT findings at the follow-up visit. In a previous study most of the CT findings were resolved in non-severe COVID-19 patients within 4 weeks after discharge[16,27]. However, as the severity of disease increases the recovery time may be longer. In a large cohort, patients with increased disease severity had higher CT scores at follow-up visits[28]. We found two-thirds of ICU patients had at least one of the CT findings at follow-up visits; irregular lines, subpleural lines and GGO were the most common patterns in chest CT. We also found advanced age and higher CT scores at admission were risk factors for having abnormal CT findings at the follow-up visit. Disease severity was found to be an independent risk factor for percentage change of CT score in the previous study[28]. Positive pressure ventilation or higher levels of fraction of inspired oxygen (FiO_2), which are frequently used in serious patients, may themselves cause lung damage and may inhibit complete recovery[29–31].

We found PFT impairment was more frequent in individuals who were discharged from ICU. Patients with severe disease were more prone to PFT impairment at the early convalescence phase and long-term[27,28]. Patients with PFT impairment had higher CT scores at the follow-up visit despite these patients having had lower CT scores at admission (Table-4). It is difficult to associate changes in pulmonary function tests with COVID-19, since the baseline pulmonary function status of patients is not fully known. Nevertheless, patients with impaired PFT had higher scores at the follow-up CT, suggesting a relationship between partial improvement in CT findings and PFT impairment.

Median distance of 6-min walk was similar in both the patients discharged from ICU and from the medical ward, and these results are consistent with a previous study[28]. However, in half of the patients discharged from the ICU, when the patients were stratified into age and weight, the 6-minute walk test was found to be less than 80% of the expected value. Immobilization, severity of illness, and use of corticosteroids are risk factors for reduced exercise capacity[32]. ICU patients had these risk factors, thus reduced exercise capacity could be expected in these patients. Prolonged immobilization after hospital discharge and restrictions to prevent transmission, such as general curfew, may have limited the mobilization of these patients in the recovery phase.

We found 79% of participants had at least one persistent symptom and patients with severe disease had a higher percentage of persistent symptoms. The percentage of residual symptoms in COVID-19 varies from 49% to 79% in previous studies[14,28]. Effort dyspnea, fatigue and muscle weakness were the most common persistent symptoms in our and a previous study[28].

Impairment of quality of life was observed in SF-36 categories, especially social functioning, role limitation due to physical and emotional problems. Impairment of quality of life was similar in both ICU and non-ICU patients. This result is consistent with long term follow up in SARS patients[24]. The percentage of residual symptoms and impairment of health status were significantly higher in female participants. Female survivors were more prone to depression and anxiety after the previous SARS outbreak[33]. Severity of disease and female gender were found to be risk factors for persistent psychological symptoms[28]. Not just disease-related causes, but also social restrictions (such as quarantine, and curfew to prevent spread of the disease), increased stress, anxiety, and depression in females[34]. Psychological distress, anxiety and depression may aggravate persistent symptoms and influence the impairment of quality of life.

This study has several limitations. This is a single-centre study so these results cannot be generalized to other centres. Although the desired number of patients could not be reached in the ICU patients group, the study has enough power (0.83) to test the difference between the two groups for the primary outcome. We could not measure diffusion of carbon monoxide (DLCO), which is frequently impaired in patients with SARS or COVID-19, due to technical reasons in our pulmonary functional centre. The baseline data of PFT and 6-min walking distance were unknown so we cannot directly associate COVID-19 and PFT or 6-min walking impairment. The fact that the majority of the participants were men may have affected the results especially the assessment of quality of life.

Conclusion

This study is one of the first studies comparing the long-term outcomes of patients with COVID-19 who were admitted to ICU and medical wards. A number of COVID-19 survivors could not fully recover within 6 months of hospital discharge. Unresolved CT findings, impaired PFT, and decreased exercise capacity might be persistent in ICU patients even after 6 months. COVID-19 survivors need to be followed up on and be supported by psychotherapeutic approaches if necessary.

Acknowledgments

References

1. WHO Coronavirus (COVID-19) Dashboard | WHO Coronavirus (COVID-19) Dashboard With Vaccination Data. Data last updated: April 28 2021.

2. Wang D, Hu B, Hu C, et al. Clinical Characteristics of 138 Hospitalized Patients with 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. *JAMA - J Am Med Assoc* . 2020;323(11):1061-1069.

3. Cummings MJ, Baldwin MR, Abrams D, et al. Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study. *medRxiv* . 2020;6736(20):2020.04.15.20067157.

4. Bernheim A, Mei X, Huang M, et al. Chest CT findings in coronavirus disease 2019 (COVID-19): Relationship to duration of infection.*Radiology* . 2020;295(3):685-691.

5. Fang Y, Zhang H, Xie J, et al. Sensitivity of Chest CT for COVID-19: Comparison to RT-PCR. *Radiology* . 2020. doi:10.1148/radiol.2020200432

6. Li K, Fang Y, Li W, et al. CT image visual quantitative evaluation and clinical classification of coronavirus disease (COVID-19). *Eur Radiol* . 2020;30(8):4407-4416.

7. Yang R, Li X, Liu H, et al. Chest CT Severity Score: An Imaging Tool for Assessing Severe COVID-19. *Radiol Cardiothorac Imaging* . 2020;2(2):e200047.

8. Wu Z, McGoogan JM. Characteristics of and Important Lessons from the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72314 Cases from the Chinese Center for Disease Control and Prevention. *JAMA - J Am Med Assoc* . 2020;2019.

9. Docherty AB, Harrison EM, Green CA, et al. Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: Prospective observational cohort study.*BMJ* . 2020;369:1-2.

10. Grasselli G, Zangrillo A, Zanella A, et al. Baseline Characteristics and Outcomes of 1591 Patients Infected with SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy. *JAMA - J Am Med Assoc* . 2020:1-8.

11. Wang Y, Lu X, Li Y, et al. Clinical course and outcomes of 344 intensive care patients with COVID-19. *Am J Respir Crit Care Med* . 2020;201(11):1430-1434.

12. Petrilli CM, Jones SA, Yang J, et al. Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: Prospective cohort study.*BMJ* . 2020;369.

13. Richardson S, Hirsch JS, Narasimhan M, et al. Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area. *JAMA* . 2020;323(20):2052.

14. Xiong Q, Xu M, Li J, et al. Clinical sequelae of COVID-19 survivors in Wuhan, China: a single-centre longitudinal study. *Clin Microbiol Infect* . 2021;27(1):89-95.

15. Carfì A, Bernabei R, Landi F. Persistent symptoms in patients after acute COVID-19. *JAMA - J Am Med Assoc* . 2020;324(6):603-605.

16. Liu C, Ye L, Xia R, et al. Chest computed tomography and clinical follow-Up of discharged patients with COVID-19 in Wenzhou city, Zhejiang, China. *Ann Am Thorac Soc* . 2020;17(10):1231-1237.

17. Yelin D, Wirtheim E, Vetter P, et al. Long-term consequences of COVID-19: research needs. *Lancet Infect Dis* . 2020;20(10):1115-1117.

18. Organization WH. Global surveillance for COVID-19 disease caused by human infection with novel coronavirus (COVID-19): interim guidance, 27 February 2020. 2020;(February):27-29.

19. Türkiye Cumhuriyeti Sağlık Bakanlığı Halk Sağlığı Genel Müdürlüğü. COVID-19 Rehberi. 2020;2 Nisan 20:25.

20. Graham BL, Steenbruggen I, Barjaktarevic IZ, et al. Standardization of spirometry 2019 update an official American Thoracic Society and European Respiratory Society technical statement. *Am J Respir Crit Care Med* . 2019;200(8):E70-E88.

21. Ding X, Xu J, Zhou J, Long Q. Chest CT findings of COVID-19 pneumonia by duration of symptoms. *Eur J Radiol* . 2020;127.

22. Ruta DA, Abdalla MI, Garratt AM, Coutts A, Russell IT. SF 36 health survey questionnaire: I. Reliability in two patient based studies.*Qual Health Care* . 1994;3(4):180-185.

23. Bilir Kaya B, İçağasıoğlu A. Reliability and validity of the Turkish version of short form 36 (SF-36) in patients with rheumatoid arthritis.*J Surg Med* . 2018;2(1).

24. Hui DS, Joynt GM, Wong KT, et al. Impact of severe acute respiratory syndrome (SARS) on pulmonary function, functional capacity and quality of life in a cohort of survivors. *Thorax* . 2005;60(5):401-409.

25. Francone M, Iafrate F, Masci GM, et al. Chest CT score in COVID-19 patients: correlation with disease severity and short-term prognosis.*Eur Radiol* . 2020;30(12):6808-6817.

26. Kazemi MA, Ghanaati H, Moradi B, et al. Prognostic factors of chest CT findings for ICU admission and mortality in patients with COVID-19 pneumonia. *medRxiv* . November 2020:2020.10.30.20223024.

27. Huang Y, Tan C, Wu J, et al. Impact of coronavirus disease 2019 on pulmonary function in early convalescence phase. *Respir Res* . 2020;21(1):1-10.

28. Huang C, Huang L, Wang Y, et al. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. *Lancet (London, England)* . 2021:1-12.

29. Kallet RH, Matthay MA. Hyperoxic acute lung injury. In:*Respiratory Care* . Vol 58. Respiratory Care; 2013:123-140.

30. Boussarsar M, Thierry G, Jaber S, Roudot-Thoraval F, Lemaire F, Brochard L. Relationship between ventilatory settings and barotrauma in the acute respiratory distress syndrome. *Intensive Care Med* . 2002;28(4):406-413.

31. Robba C, Ball L, Pelosi P. Between hypoxia or hyperoxia: Not perfect but more physiologic. *J Thorac Dis* . 2018;10(Suppl 17):S2052-S2054.

32. Herridge MS. Recovery and Long-Term Outcome in Acute Respiratory Distress Syndrome. *Crit Care Clin* . 2011;27(3):685-704.

33. Lee AM, Wong JGWS, McAlonan GM, et al. Stress and psychological distress among SARS survivors 1 year after the outbreak. *Can J Psychiatry* . 2007;52(4):233-240.

34. Al Dhaheri AS, Bataineh MF, Mohamad MN, et al. Impact of COVID-19 on mental health and quality of life: Is there any effect? A crosssectional study of the MENA region. *PLoS One* . 2021;16(3 March).

Table 1. Demographic and clinical characteristics of the patients

Patient characteristics	ICU patients (n=31)	Non-ICU patients (n=39)	p
Age, years	59 (48-65)	56 (48-61)	0.40
Male gender, n (%)	26 (84)	24 (62)	0.04
BMI, kg/m^2	31 (29-35)	30 (25-34)	0.20
Smoking Status, n (%)			
None	14 (45)	27 (69)	
Active Smoker	0 (0)	2 (5)	
Former Smoker	17 (55)	10 (26)	
Smoking time, years	30 (10-40)	15 (13-25)	0.25
Comorbidities, n (%)			
COPD	5 (16)	2 (5)	0.13 0.07 0.15 0.46 0.86 0.11
Hypertension	16 (52)	12 (31)	
DM	13 (42)	10 (26)	
CAD	3 (10)	2 (5)	
CHF	1 (3)	1 (2)	
Malignancy	0 (0)	3 (8)	
Charlson Comorbidity Index	1 (1-2)	1 (1-2)	0.16
Disease Severity			
1- No O$_2$ Therapy	0 (0)	18 (46)	<0.001
2- Only O$_2$ Therapy	3 (10)	21 (54)	
3- NIV or HFNC	23 (74)	0 (0)	
4- IMV	5 (16)	0 (0)	
APACHE-2 Score	11 (8-15)	-	
Treatment, n (%)			
Hydroxychloroquine	21 (68)	33 (85)	0.09 <0.001 <0.001 <0.001 0.009 0.2
Favipravir	31 (100)	19 (49)	
Corticosteroid	26 (83)	3 (8)	
Convalescent plasma	12 (39)	0 (0)	
Tocilizumab	5 (16)	0 (0)	
Antibiotics	31 (100)	37 (95)	
Complications, n (%)			
Acute renal failure	4 (13)	2 (5)	0.39 0.045 0.26
Hepatotoxicity	9 (29)	4 (10)	
Sepsis	1 (3)	0 (0)	
Length of hospital stay, days	19 (14-28)	8 (6-11)	<0.001
Length of ICU stay, days	9 (6-15)	-	
Time from symptoms to follow up, days	209 (189-219)	190 (186-209)	0.016

APACE-2, Acute Physiology and Chronic Health Evaluation; BMI, Body Mass Index; CHF, Congestive Heart

Failure; COPD, Chronic Obstructive Pulmonary Disease; CAD, Coronary Arterial Disease; DM, Diabetes Mellitus; HFNO, High Flow Nasal Oxygen; ICU, intensive care unit IMV, Invasive Mechanical ventilation; NIV, Non-invasive Mechanical Ventilation

Data are shown as n (%) and median ($25^{th} - 75^{th}$ percentiles)

Table 2. Chest CT scores and findings at admission and 6-months follow up

CT findings	ICU patients (n=31)	Non-ICU patients (n=39)	p
CT score at admission, points	17 (11-24)	11 (10-15)	0.002
Number of patients having at least one CT finding at admission, n %	31 (100%)	39 (100%)	0.36
CT score at 6 months follow-up visit	6 (0-10)	0 (0-3)	0.001
Number of patients having at least one CT finding at 6 months follow up visit, n %	20 (65%)	12 (31%)	0.005

CT, Computerized Tomography; ICU, Intensive Care Unit

Data are shown as n (%) and median ($25^{th} - 75^{th}$ percentiles)

Table 3. Results of pulmonary function tests, 6-MWD an quality of life scores at follow-up visit

Parameters	ICU patients (n=31)	Non-ICU patients (n=39)	p
FVC, % of predicted	85 (77-97)	95 (85-104)	0.73
FEV1, % of predicted	95 (84-103)	99 (86-106)	0.18
FEV1/FVC, % of predicted	112 (108-116)	109 (102-114)	0.94
PIF, % of predicted	96 (76-127)	100 (64-132)	0.98
PEF, % of predicted	90 (64-110)	79 (68-96)	0.42
6MWD, meters	445 (346-515)	461 (390-527)	0.31
FVC< 80% of predicted, n%	9 (31%)	5 (14%)	0.09
FEV1< 80% of predicted, n%	6 (21%)	7 (19%)	0.9
FEV1/FVC< 80% of predicted, n%	2 (7%)	0 (0%)	0.10
PIF< 80% of predicted, n%	8 (28%)	12 (33%)	0.61
PEF< 80% of predicted, n%	12 (41%)	19 (49%)	0.36
6MWD< 80% of mean distance	13 (42%)	11 (28%)	0.22
SF-36 Categories			
Physical functioning	80 (45-90)	80 (65-95)	0.48

Parameters	ICU patients (n=31)	Non-ICU patients (n=39)	p
Social functioning	50 (25-75)	63 (38-75)	0.23
Role limitation due to physical problems	50 (0-100)	50 (25-100)	0.16
Role limitation due to emotional problems	33 (0-100)	67 (0-100)	0.49
General health	65 (40-80)	60 (45-80)	0.79
Mental health	68 (48-84)	68 (52-76)	0.43
Bodily pain	88 (55-100)	90 (58-100)	0.81
Vitality	65 (40-80)	60 (45-80)	0.68

6MWD, 6-Minute Walking Distance; FEV1, Forced Expiratory Volume in One Second; FVC, Forced Vital Capacity; ICU, Intensive Care Unit; PEF, Peak Expiratory Flow; PIF, Peak Inspiratory Flow; SF-36, Short Form-36

Data are shown as n (%) and median (25th – 75th percentiles)

Table 4. Association between CT scores and pulmonary functional test impairment

	FVC< 80% of predicted	FVC[?] 80% of predicted	p
CT scores at admission	11 (9-20)	14 (10-17)	0.78
CT scores at 6 months follow-up	7 (4-10)	0 (0-4)	0.007
	FEV1< 80% of predicted	**FEV1[?] 80% of predicted**	
CT scores at admission	10 (10-11)	15 (11-18)	0.11
CT scores at 6 months follow-up	5 (0-10)	0 (0-5)	0.036
	FEV1/FVC< 80% of predicted	**FEV1/FVC[?] 80% of predicted**	
CT scores at admission	6 (3-8)	14 (10-18)	0.024
CT scores at 6 months follow-up	5 (0-10)	1 (0-8)	0.80
	PIF< 80% of predicted	**PIF[?] 80% of predicted**	
CT scores at admission	11 (10-14)	15 (11-18)	0.07
CT scores at 6 months follow-up	3 (0-7)	0 (0-9)	0.55
	PEF< 80% of predicted	**PEF[?] 80% of predicted**	
CT scores at admission	11 (8-15)	15 (12-19)	0.006
CT scores at 6 months follow-up	2 (0-6)	0 (0-8)	0.19

CT, Computerized Tomography, FEV1, Forced Expiratory Volume in One Second; FVC, Forced Vital Capacity; ICU, Intensive Care Unit; PEF, Peak Expiratory Flow; PFT, Pulmonary Functional Test; PIF, Peak Inspiratory Flow

Data are shown as median (25th – 75th percentiles)

Figure Legend

Figure 1. Flow chart of patients who admitted to hospital with suspect of COVID-19 during 19 March and 1 September 2020.

COVID-19, Coronavirus Disease-19; HRCT, High Resolution Computerized Tomography; ICU, Intensive Care Unit; PCR, Polymerase Chain Reaction